

Elisabeth Maillart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1292369/publications.pdf>

Version: 2024-02-01

68
papers

2,138
citations

361413

20
h-index

254184

43
g-index

76
all docs

76
docs citations

76
times ranked

2427
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. <i>Neurology</i> , 2018, 90, e1858-e1869.	1.1	401
2	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1079.	9.0	357
3	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.	5.3	123
4	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	7.2	115
5	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	2.0	110
6	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. <i>Neurology</i> , 2020, 94, e1645-e1656.	1.1	66
7	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	3.5	58
8	Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 24-31.	1.9	57
9	Efficacy of rituximab in refractory neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 955-959.	3.0	55
10	Adaptive human immunity drives remyelination in a mouse model of demyelination. <i>Brain</i> , 2017, 140, 967-980.	7.6	53
11	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. <i>Revue Neurologique</i> , 2018, 174, 255-264.	1.5	47
12	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	3.6	47
13	MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. <i>European Journal of Neurology</i> , 2020, 27, 429-436.	3.3	39
14	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>JAMA Neurology</i> , 2022, 79, 518.	9.0	39
15	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	3.0	37
16	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. <i>JAMA Neurology</i> , 2020, 77, 94.	9.0	36
17	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	7.2	30
18	The cerebrospinal fluid $CD4/CD8$ ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study. <i>European Journal of Neurology</i> , 2019, 26, 1274-1280.	3.3	28

#	ARTICLE	IF	CITATIONS
19	Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102482.	2.0	28
20	The long-term outcome of MOGAD: An observational national cohort study of 61 patients. <i>European Journal of Neurology</i> , 2021, 28, 1659-1664.	3.3	26
21	Fast multiple sclerosis progression in North Africans. <i>Neurology</i> , 2017, 88, 1218-1225.	1.1	24
22	Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. <i>Neurology</i> , 2021, 96, e2006-e2015.	1.1	22
23	A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2025-2037.	3.7	20
24	Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. <i>European Journal of Neurology</i> , 2020, 27, 384-391.	3.3	19
25	Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. <i>European Journal of Neurology</i> , 2021, 28, 3461-3466.	3.3	17
26	MRI characteristics of MOG-Ab associated disease in adults: An update. <i>Revue Neurologique</i> , 2021, 177, 39-50.	1.5	15
27	Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e997.	6.0	15
28	Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies. <i>Neurology</i> , 2015, 85, 1630-1632.	1.1	14
29	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020, 17, 128.	7.2	13
30	Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1155-1159.	3.0	13
31	Natalizumab-PML survivors with subsequent MS treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e346.	6.0	12
32	Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560886.	1.0	11
33	Spontaneous remyelination in lesions protects the integrity of surrounding tissues over time in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1719-1729.	3.3	11
34	Extensive and severe CNS demyelination associated with golimumab therapy. <i>Journal of Neurology</i> , 2016, 263, 1869-1871.	3.6	10
35	Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML. <i>European Radiology</i> , 2021, 31, 2944-2955.	4.5	10
36	Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center. <i>Frontiers in Neurology</i> , 2017, 8, 183.	2.4	9

#	ARTICLE	IF	CITATIONS
37	Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy. <i>Multiple Sclerosis Journal</i> , 2018, 24, 313-321.	3.0	9
38	Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	9
39	COVID-19 infection in NMO/SD patients: a French survey. <i>Journal of Neurology</i> , 2021, 268, 1188-1190.	3.6	9
40	Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2280-2283.	3.0	9
41	Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 505-509.	3.0	8
42	Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data. <i>BMC Medical Research Methodology</i> , 2021, 21, 95.	3.1	8
43	Spinal Koebner phenomenon: Medullar sarcoidosis facing a discal hernia. <i>Joint Bone Spine</i> , 2017, 84, 497-498.	1.6	7
44	Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1794-1798.	3.0	7
45	Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102981.	2.0	7
46	Treatment of progressive multiple sclerosis: Challenges and promising perspectives. <i>Revue Neurologique</i> , 2018, 174, 441-448.	1.5	6
47	Severe transient myopathy in a patient with progressive multiple sclerosis and high-dose biotin. <i>Neurology</i> , 2019, 92, 1060-1062.	1.1	6
48	Comparative effectiveness of dimethyl fumarate in multiple sclerosis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1268-1278.	2.4	6
49	Favorable outcome of a pregnancy after fampridine exposition during the first month. <i>Journal of the Neurological Sciences</i> , 2016, 370, 158.	0.6	5
50	Extensive white matter lesions after 2â€‰years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 614-616.	3.0	5
51	Fatigue evaluation in fingolimod treated patients: An observational study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 8-11.	2.0	5
52	Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021, 18, 378-386.	4.4	5
53	Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination. <i>Journal of Neurology</i> , 2022, 269, 5647-5650.	3.6	5
54	Pure Relapsing Short Myelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	5

#	ARTICLE	IF	CITATIONS
55	Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 220-222.	2.0	4
56	Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartiment imaging study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1881-1890.	3.0	3
57	False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin. <i>Multiple Sclerosis Journal</i> , 2020, 26, 257-258.	3.0	2
58	'Balloon pressure technique' for endovascular treatment of spinal cord arteriovenous fistulas: preliminary results in 10 cases. <i>Journal of NeuroInterventional Surgery</i> , 2023, 15, 276-282.	3.3	2
59	Early radiological features of severe longitudinally extensive transverse myelitis over time. <i>Journal of the Neurological Sciences</i> , 2019, 400, 7-9.	0.6	1
60	A comparative evaluation of different neuromyelitis optica spectrum disorder sets of criteria. <i>European Journal of Neurology</i> , 2020, 27, 2250-2256.	3.3	1
61	Headache and multifocal white matter lesions: Radiologically Isolated Syndrome or CADASIL?. <i>Revue Neurologique</i> , 2020, 176, 880-881.	1.5	1
62	Multiple cervical dissections after Rituximab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102105.	2.0	1
63	Unexpected REM sleep excess associated with a pontine lesion in multiple sclerosis. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 1117-1119.	2.6	1
64	Leucoencefalopatia multifocale progressiva. <i>EMC - Neurologia</i> , 2018, 18, 1-10.	0.0	0
65	Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 528-538.	3.0	0
66	Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 628375.	4.8	0
67	La moelle se traite-elle comme le cerveau?. <i>Pratique Neurologique - FMC</i> , 2022, 13, 71-71.	0.1	0
68	Author Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD. <i>Neurology</i> , 2021, 96, 295-296.	1.1	0